- Home
- FEMY vs CYCC Comparison
FEMY vs CYCC Comparison
Compare FEMY & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- CYCC
- Stock Information
- Founded
- FEMY 2004
- CYCC 1992
- Country
- FEMY United States
- CYCC Malaysia
- Employees
- FEMY N/A
- CYCC N/A
- Industry
- FEMY Medical/Dental Instruments
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- CYCC Health Care
- Exchange
- FEMY Nasdaq
- CYCC Nasdaq
- Market Cap
- FEMY 18.6M
- CYCC 17.5M
- IPO Year
- FEMY 2021
- CYCC N/A
- Fundamental
- Price
- FEMY $0.38
- CYCC $7.12
- Analyst Decision
- FEMY Strong Buy
- CYCC
- Analyst Count
- FEMY 3
- CYCC 0
- Target Price
- FEMY $7.33
- CYCC N/A
- AVG Volume (30 Days)
- FEMY 1.6M
- CYCC 86.9K
- Earning Date
- FEMY 08-08-2025
- CYCC 08-13-2025
- Dividend Yield
- FEMY N/A
- CYCC N/A
- EPS Growth
- FEMY N/A
- CYCC N/A
- EPS
- FEMY N/A
- CYCC N/A
- Revenue
- FEMY $1,887,016.00
- CYCC $10,000.00
- Revenue This Year
- FEMY $103.55
- CYCC $137.21
- Revenue Next Year
- FEMY $148.13
- CYCC N/A
- P/E Ratio
- FEMY N/A
- CYCC N/A
- Revenue Growth
- FEMY 98.61
- CYCC N/A
- 52 Week Low
- FEMY $0.31
- CYCC $3.08
- 52 Week High
- FEMY $1.80
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- FEMY 24.33
- CYCC 41.06
- Support Level
- FEMY $0.36
- CYCC $7.30
- Resistance Level
- FEMY $0.42
- CYCC $8.82
- Average True Range (ATR)
- FEMY 0.06
- CYCC 0.63
- MACD
- FEMY -0.01
- CYCC 0.03
- Stochastic Oscillator
- FEMY 16.48
- CYCC 17.87
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.